Compare CSTL & FLNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSTL | FLNG |
|---|---|---|
| Founded | 2007 | 2006 |
| Country | United States | Bermuda |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Marine Transportation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.4B |
| IPO Year | 2019 | N/A |
| Metric | CSTL | FLNG |
|---|---|---|
| Price | $32.44 | $26.04 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 1 |
| Target Price | ★ $46.67 | $23.00 |
| AVG Volume (30 Days) | ★ 407.5K | 339.5K |
| Earning Date | 02-26-2026 | 02-11-2026 |
| Dividend Yield | N/A | ★ 11.49% |
| EPS Growth | N/A | ★ 7.64 |
| EPS | N/A | ★ 1.82 |
| Revenue | $343,530,000.00 | ★ $351,034,000.00 |
| Revenue This Year | $2.88 | N/A |
| Revenue Next Year | N/A | $3.52 |
| P/E Ratio | ★ N/A | $14.34 |
| Revenue Growth | ★ 10.15 | N/A |
| 52 Week Low | $14.59 | $19.46 |
| 52 Week High | $44.28 | $27.67 |
| Indicator | CSTL | FLNG |
|---|---|---|
| Relative Strength Index (RSI) | 24.66 | 49.50 |
| Support Level | $38.20 | $25.88 |
| Resistance Level | $40.88 | $26.85 |
| Average True Range (ATR) | 1.98 | 0.57 |
| MACD | -1.10 | -0.08 |
| Stochastic Oscillator | 3.79 | 22.14 |
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
Flex LNG Ltd is an LNG shipping company with a fleet of next-generation LNG carriers with large cargo capacity. The fleet consists of thirteen modern LNG ships, ten existing and three under construction for delivery. All LNG carriers are equipped with slow-speed, two-stroke engines MEGI or X-DF propulsion which will provide Charterers with tonnage offering advantages in form of reduced fuel consumption and lowered boil-off rates.